Nashville-based eye care pharmaceutical company Harrow Inc. announced Friday it has entered into an agreement to acquire Melt Pharmaceuticals Inc.

Mark Baum Hamilton Matthew Masters

Financial terms of the deal were not disclosed in a release.

The closing is subject to approval by Melt stockholders and affiliates.

Melt, formerly a Harrow subsidiary, is a clinical-stage company developing non-opioid, non-IV sedation therapies. Its MELT-300 uses Catalent’s ZYDIS orally dissolving tablet technology, which Harrow said is used in more than 35 Food and Drug Administration-approved products.

Harrow said patents for the MELT-300 program have been issued in North America, Australia, Europe, Asia and the Middle East, and it plans to seek partners for markets outside the United States.

Harrow

See Full Page